The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome

The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome

Patients with obstructive sleep apnea (OSA) have high rates of co-occurring type 2 diabetes, hypertension, obesity, stroke, congestive heart failure, and accelerated atherosclerotic cardiovascular diseases. These conditions frequently require multiple medications, raising the risk of polypharmacy, a...

Full description

Bibliographic Details
Main Authors: Rizwana Sultana, Fatoumatta Sissoho, Vinod P. Kaushik, Mukaila A. Raji
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Life
Subjects:
diabetes
obesity
obstructive sleep apnea
GLP I-RA
Online Access:https://www.mdpi.com/2075-1729/12/8/1222

Internet

https://www.mdpi.com/2075-1729/12/8/1222

Similar Items